Investors

Watch hVIVO’s July 2024 Capital Markets Day here

hVIVO is a publicly traded company on the London Stock Exchange AIM Market under the symbol HVO

Yamin 'Mo' Khan

CEO at hVIVO

“After an exceptionally strong first half with record revenues and margins, hVIVO enters the remainder of the year with FY24 revenue guidance fully contracted and good visibility into 2025. We continue to expand our pipeline, not only in human challenge trials but also in our new revenue streams including clinical site studies, standalone laboratory services, and volunteer / patient recruitment. Operational efficiencies are set to continue to improve with the expansion of our services, improved automation, and the move to our new facility in Canary Wharf."

See Results Centre
Regulatory News

Investment Case

World Leading Capabilities

  • Expertise & history
  • Canary Wharf 50-bed facility
  • FluCamp volunteer database

Robust Financials

  • Record H1 24 & FY 23
  • Cash generative, dividend
  • Strong EBITDA margin

Clear Growth Strategy

  • Expanding services
  • M&A
  • £100m revenue target by 2028

Positive Market Dynamics

  • Growing adoption of HCT
  • Strong sales pipeline
  • Long-term orderbook growth

High Barriers to Entry

  • Optimised, robust models
  • Extensive expertise & history
  • Facility, FluCamp, USP

Trusted Partner

  • 4/10 top global pharma
  • Large no. biotech clients
  • Fast track / breakthrough

End-To-End Early Clinical Development Services

hVIVO
Venn Life Sciences
hLAB
FluCamp

A rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials, providing end-to-end early clinical development services for our broad and longstanding global client base of biopharma companies.

Learn more
Two lab technicians inspecting test tubes

Venn Life Sciences is an Integrated Drug Development partner offering a unique combination of drug development consultancy, clinical trial design and execution.

Visit Venn Life

hLAB is a highly specialised virology and immunology laboratory offering a suite of services to support pre-clinical and clinical respiratory drug and vaccine discovery & development.

Visit hLAB

FluCamp welcomes volunteers to take part in our clinical trials under expertly supervised conditions.

Visit FluCamp

Latest Presentation Deck

10 Sep 2024
H1 24 Results
Download

Latest Investor Presentation

10 Sep 2024
H1 24 Results
See more
Meet our experienced executive management team
Meet the team

Capital Markets Day – July 2024

July 2024
Capital Markets Day 2024

Combined Services

hVIVO Capability
Venn Life Sciences Capability
CMC
Preclinical
Phase I
Challenge
Study
Lab Services
Phase II
Biometrics
Regulatory
Venn Breda
Venn Paris
Biobank
Manchester
Dublin
Plumbers Row
Whitechapel Hotel
QMB
hVIVO's Location
Venn Location

Quick Links

Contact our Investor Relations team.

IR@hVIVO.com
chevron-downarrow-up